Recent Updates
Recently added Catalysts
MIRA Positive Sentiment

MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2

Thursday, May 14, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: MIRA Pharmaceuticals has reported positive unblinded results from its Phase 1 clinical trial of Ketamir-2, a selective oral NMDA receptor modulator. The trial demonstrated a favorable safety and tolerability profile, which supports the company's plans for Phase 2a development targeting chemotherapy-induced peripheral neuropathy. This advancement marks a significant step for MIRA in its drug development pipeline.
Price reaction · baseline $0.971 (2026-05-13 close) · hit pre-market · clean, no other MIRA news in the window
day 0 close
+0.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive unblinded results from Phase 1 trial.
  • Favorable safety and tolerability profile for Ketamir-2.
  • Supports planned Phase 2a development.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+5%
120-day peak, hindsight
Typical move
0.6%
average across 2 past catalysts
Cash runway
~21 mo
Low dilution risk

Full Press Release Details

Selective oral NMDA receptor modulator demonstrated favorable safety, tolerability, and pharmacokinetic profile supporting planned Phase 2a development in chemotherapy-induced peripheral neuropathy MIAMI, FL / ACCESS Newswire / May 14, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), today announced positive unblinded results from its completed Phase 1 clinical trial evaluating Ketamir-2, the Company’s proprietary selective oral NMDA receptor modulator. Th…
You can read the full content here

Frequently Asked Questions

What are the results of MIRA's Phase 1 trial?

MIRA reported positive unblinded results from its Phase 1 trial of Ketamir-2.

What is Ketamir-2 used for?

Ketamir-2 is a selective oral NMDA receptor modulator aimed at treating chemotherapy-induced peripheral neuropathy.

What does favorable safety profile mean?

A favorable safety profile indicates that Ketamir-2 was well tolerated by participants in the trial.

What are the next steps for MIRA Pharmaceuticals?

MIRA plans to advance Ketamir-2 into Phase 2a development following the positive Phase 1 results.

ShareAdd on Google
Tags: MIRA Viatris Investor Conferences Healthcare MIRA Pharmaceuticals Ketamir-2 Phase 1 trial chemotherapy-induced neuropathy NMDA receptor modulator
Last updated: May 14, 2026

Biotech snapshot

Cash runway
$9M liquidity · $0M/mo burn
~21 mo
Low dilution risk

Catalyst track record

+5%
best trade around MIRA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for MIRA.

See every catalyst's timing & PoA →